THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 116 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,479,684 | -16.6% | 287,333 | 0.0% | 0.32% | -31.6% |
| Q2 2023 | $2,973,897 | +43912.1% | 287,333 | -53.9% | 0.46% | -56.5% |
| Q1 2023 | $6,757 | -29.2% | 622,738 | -26.8% | 1.06% | -52.5% |
| Q4 2022 | $9,548 | -99.9% | 850,988 | -26.7% | 2.24% | -18.4% |
| Q3 2022 | $11,768,000 | +11.9% | 1,160,503 | 0.0% | 2.74% | +10.4% |
| Q2 2022 | $10,514,000 | -5.7% | 1,160,503 | -0.5% | 2.48% | +64.2% |
| Q1 2022 | $11,152,000 | -20.0% | 1,166,574 | -7.5% | 1.51% | -18.7% |
| Q4 2021 | $13,941,000 | -0.4% | 1,261,674 | -33.3% | 1.86% | -6.2% |
| Q3 2021 | $14,004,000 | -23.6% | 1,892,452 | +50.0% | 1.98% | -1.3% |
| Q2 2021 | $18,320,000 | -20.9% | 1,261,718 | +11.2% | 2.01% | -18.6% |
| Q1 2021 | $23,160,000 | +14.9% | 1,134,718 | 0.0% | 2.47% | +0.4% |
| Q4 2020 | $20,164,000 | +17.8% | 1,134,718 | -2.0% | 2.46% | -11.2% |
| Q3 2020 | $17,117,000 | -25.7% | 1,157,718 | +5.5% | 2.77% | -28.7% |
| Q2 2020 | $23,041,000 | -0.6% | 1,097,718 | +9.5% | 3.88% | -31.5% |
| Q1 2020 | $23,173,000 | -5.7% | 1,002,718 | +5.7% | 5.67% | +56.8% |
| Q4 2019 | $24,570,000 | +83.0% | 949,006 | +37.7% | 3.61% | +89.2% |
| Q3 2019 | $13,427,000 | +28.4% | 689,284 | +7.6% | 1.91% | +83.3% |
| Q2 2019 | $10,458,000 | +2.8% | 640,449 | +42.7% | 1.04% | -13.7% |
| Q1 2019 | $10,176,000 | -4.2% | 448,864 | +8.2% | 1.21% | -52.9% |
| Q4 2018 | $10,618,000 | -20.5% | 414,921 | +1.5% | 2.56% | +87.2% |
| Q3 2018 | $13,359,000 | +46.0% | 408,921 | +1.4% | 1.37% | +29.4% |
| Q2 2018 | $9,147,000 | +7.6% | 403,321 | +15.0% | 1.06% | -16.5% |
| Q1 2018 | $8,503,000 | +4.1% | 350,631 | +19.7% | 1.27% | -4.9% |
| Q4 2017 | $8,172,000 | -15.2% | 293,017 | +4.1% | 1.33% | -29.0% |
| Q3 2017 | $9,640,000 | +9.4% | 281,537 | +27.3% | 1.88% | +26.2% |
| Q2 2017 | $8,809,000 | +9.1% | 221,117 | +0.8% | 1.49% | +34.1% |
| Q1 2017 | $8,075,000 | -6.9% | 219,303 | -19.4% | 1.11% | -65.2% |
| Q4 2016 | $8,676,000 | – | 272,153 | – | 3.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |